InMed Pharmaceuticals Inc. Income Statement

Income Statement Jun2022 Jun2023 Jun2024 Jun2025
Revenue & cost
Revenue 1.09M4.14M4.60M4.94M
Cost of Revenue 0.55M2.73M3.50M3.24M
Gross Profit 0.54M1.40M1.10M1.71M
Operating items
Depreciation & Amortization - Total 0.04M0.05M0.05M
Research & Development 7.28M3.73M3.22M2.85M
Selling, General & Administrative 6.87M5.85M5.80M6.56M
Restructuring Costs 0.29M0.06M0.16M
Other Operating Expenses -19.26M-19.26M0.07M0.19M
Operating Expenses 17.81M9.83M9.30M9.65M
Operating Income -17.26M-8.43M-8.20M-7.95M
EBIT -17.26M-8.43M-8.20M-7.95M
Non-operating items
Interest & Investment Income 0.10M0.49M0.53M0.16M
Other Non Operating Income -0.12M-0.05M-0.06M-0.03M
Non Operating Income 0.49M0.53M
Net income details
EBT -18.60M-7.93M-7.67M-8.16M
Tax Provisions 0.01M0.01M
Profit After Tax -18.60M-7.95M-7.70M-8.20M
Income from Continuing Operations -18.60M-7.95M-7.68M-8.16M
Consolidated Net Income -18.60M-7.95M-7.68M-8.16M
Income towards Parent Company -18.60M-7.95M-7.68M-8.16M
Net Income towards Common Stockholders -18.60M-7.95M-7.68M-8.16M
Additional items
EPS (Basic) -33.17-3.25-20.14-8.36
EPS (Weighted Average and Diluted) -3.25-20.14-8.36
Shares Outstanding (Weighted Average) 0.03M0.17M0.42M1.21M
Shares Outstanding (Diluted Average) 2.45M0.38M0.98M
EBITDA -18.60M-8.39M-8.15M-7.90M